Multicenter Epidemiologic Study of Severe Community Acquired Pneumonia in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-10

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to understand the clinical characteristics, etiology and resistance phenotype of major pathogens of SCAP in China through multicenter and prospective investigation. Thus to provide epidemiological basis for improving the SCAP diagnosis and treatment protocol suitable for China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment

NCT06028217

Hospital-acquired Pneumonia Antibiotic Resistant Infection

NOT_YET_RECRUITING

Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

NCT03093220

Respiratory Infections Genetic Disorder Community-Acquired Infections +1 more

UNKNOWN

The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing

NCT01236677

Community Acquired Pneumonia

UNKNOWN

Clinical Characteristics and Microbiology of Community-Acquired Pneumonia

NCT03098914

Community-acquired Pneumonia

UNKNOWN

Assessing Effectiveness of Community Acquired Pneumonia Treatment by Continuous Pneumonia Severity Score

NCT04135183

Community-acquired Pneumonia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During the study period, all patients who are diagnosed with SCAP and meet the inclusion criteria in the participating unit should be enrolled in the study . At the end of the trial, each participating unit should complete at least 20 qualified cases, and all participating units should have a total of more than 300 qualified cases.

1. Learn about the etiology of SCAP in China.
2. Grasp the resistance phenotype and molecular epidemiology of major pathogens of SCAP in China.
3. Know the important clinical characteristics of SCAP in China, including age, basic diseases, length of hospital stay, length of stay in ICU, duration of mechanical ventilation, clinical manifestations, imaging findings, complications, mortality, etc.
4. Analyze and clarify the clinical risk factors of affecting SCAP mortality.
5. Understand the current situation of antibiotic treatment of SCAP in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SCAP groups

all the SCAP patients who meet the inclusion criteria

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 yeas;
* Diagnosis of CAP according to the diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Exclusion Criteria

* Bronchiectasis;
* Active tuberculosis;
* Aspiration pneumonia or obstructive pneumonia;
* Hospitalized in 2 weeks;
* Hospitalized or ventilated ≥5 days;
* Severe immunosuppression patients;
* Irregular follow-up and lost follow-up;
* Withdraw from the study for any reason.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No